Cargando…

Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles

Using nanoparticle-based RNA interference (RNAi), we have previously shown that silencing the host autophagic protein, Beclin1, in HIV-infected human microglia and astrocytes restricts HIV replication and its viral-associated inflammatory responses. Here, we confirmed the efficacy of Beclin1 small i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Myosotys, Soler, Yemmy, Muthu Karuppan, Mohan Kumar, Zhao, Yuling, Batrakova, Elena V., El-Hage, Nazira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915950/
https://www.ncbi.nlm.nih.gov/pubmed/33561939
http://dx.doi.org/10.3390/pharmaceutics13020223
_version_ 1783657366678405120
author Rodriguez, Myosotys
Soler, Yemmy
Muthu Karuppan, Mohan Kumar
Zhao, Yuling
Batrakova, Elena V.
El-Hage, Nazira
author_facet Rodriguez, Myosotys
Soler, Yemmy
Muthu Karuppan, Mohan Kumar
Zhao, Yuling
Batrakova, Elena V.
El-Hage, Nazira
author_sort Rodriguez, Myosotys
collection PubMed
description Using nanoparticle-based RNA interference (RNAi), we have previously shown that silencing the host autophagic protein, Beclin1, in HIV-infected human microglia and astrocytes restricts HIV replication and its viral-associated inflammatory responses. Here, we confirmed the efficacy of Beclin1 small interfering RNA (siBeclin1) as an adjunctive antiviral and anti-inflammatory therapy in myeloid human microglia and primary human astrocytes infected with HIV, both with and without exposure to combined antiretroviral (cART) drugs. To specifically target human microglia and human astrocytes, we used a nanoparticle (NP) comprised of linear cationic polyethylenimine (PEI) conjugated with mannose (Man) and encapsulated with siBeclin1. The target specificity of the PEI-Man NP was confirmed in vitro using human neuronal and glial cells transfected with the NP encapsulated with fluorescein isothiocyanate (FITC). PEI-Man-siBeclin1 NPs were intranasally delivered to healthy C57BL/6 mice in order to report the biodistribution of siBeclin1 in different areas of the brain, measured using stem-loop RT-PCR. Postmortem brains recovered at 1–48 h post-treatment with the PEI-Man-siRNA NP showed no significant changes in the secretion of the chemokines regulated on activation, normal T cell expressed and secreted (RANTES) and monocyte chemotactic protein-1 (MCP-1) and showed significant decreases in the secretion of the cytokines interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) when compared to phosphate-buffered saline (PBS)-treated brains. Nissl staining showed minimal differences between the neuronal structures when compared to PBS-treated brains, which correlated with no adverse behavioral affects. To confirm the brain and peripheral organ distribution of PEI-siBeclin1 in living mice, we used the In vivo Imaging System (IVIS) and demonstrated a significant brain accumulation of siBeclin1 through intranasal administration.
format Online
Article
Text
id pubmed-7915950
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79159502021-03-01 Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles Rodriguez, Myosotys Soler, Yemmy Muthu Karuppan, Mohan Kumar Zhao, Yuling Batrakova, Elena V. El-Hage, Nazira Pharmaceutics Article Using nanoparticle-based RNA interference (RNAi), we have previously shown that silencing the host autophagic protein, Beclin1, in HIV-infected human microglia and astrocytes restricts HIV replication and its viral-associated inflammatory responses. Here, we confirmed the efficacy of Beclin1 small interfering RNA (siBeclin1) as an adjunctive antiviral and anti-inflammatory therapy in myeloid human microglia and primary human astrocytes infected with HIV, both with and without exposure to combined antiretroviral (cART) drugs. To specifically target human microglia and human astrocytes, we used a nanoparticle (NP) comprised of linear cationic polyethylenimine (PEI) conjugated with mannose (Man) and encapsulated with siBeclin1. The target specificity of the PEI-Man NP was confirmed in vitro using human neuronal and glial cells transfected with the NP encapsulated with fluorescein isothiocyanate (FITC). PEI-Man-siBeclin1 NPs were intranasally delivered to healthy C57BL/6 mice in order to report the biodistribution of siBeclin1 in different areas of the brain, measured using stem-loop RT-PCR. Postmortem brains recovered at 1–48 h post-treatment with the PEI-Man-siRNA NP showed no significant changes in the secretion of the chemokines regulated on activation, normal T cell expressed and secreted (RANTES) and monocyte chemotactic protein-1 (MCP-1) and showed significant decreases in the secretion of the cytokines interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) when compared to phosphate-buffered saline (PBS)-treated brains. Nissl staining showed minimal differences between the neuronal structures when compared to PBS-treated brains, which correlated with no adverse behavioral affects. To confirm the brain and peripheral organ distribution of PEI-siBeclin1 in living mice, we used the In vivo Imaging System (IVIS) and demonstrated a significant brain accumulation of siBeclin1 through intranasal administration. MDPI 2021-02-06 /pmc/articles/PMC7915950/ /pubmed/33561939 http://dx.doi.org/10.3390/pharmaceutics13020223 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rodriguez, Myosotys
Soler, Yemmy
Muthu Karuppan, Mohan Kumar
Zhao, Yuling
Batrakova, Elena V.
El-Hage, Nazira
Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles
title Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles
title_full Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles
title_fullStr Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles
title_full_unstemmed Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles
title_short Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles
title_sort targeting beclin1 as an adjunctive therapy against hiv using mannosylated polyethylenimine nanoparticles
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915950/
https://www.ncbi.nlm.nih.gov/pubmed/33561939
http://dx.doi.org/10.3390/pharmaceutics13020223
work_keys_str_mv AT rodriguezmyosotys targetingbeclin1asanadjunctivetherapyagainsthivusingmannosylatedpolyethyleniminenanoparticles
AT soleryemmy targetingbeclin1asanadjunctivetherapyagainsthivusingmannosylatedpolyethyleniminenanoparticles
AT muthukaruppanmohankumar targetingbeclin1asanadjunctivetherapyagainsthivusingmannosylatedpolyethyleniminenanoparticles
AT zhaoyuling targetingbeclin1asanadjunctivetherapyagainsthivusingmannosylatedpolyethyleniminenanoparticles
AT batrakovaelenav targetingbeclin1asanadjunctivetherapyagainsthivusingmannosylatedpolyethyleniminenanoparticles
AT elhagenazira targetingbeclin1asanadjunctivetherapyagainsthivusingmannosylatedpolyethyleniminenanoparticles